98%
921
2 minutes
20
Our paper investigated the effect of berberine on the diabetic retinopathy (DR) in transgenic mice and explored its possible mechanisms. During chronic intragastric administration for ten weeks, berberine could decrease the levels of fasting blood glucose, TC and TG without hepatotoxicity. Moreover, berberine could protect the retinal morphology against the hyperglycemic insults and decrease glycogen accumulation, the contents of TNF-α and IL-1β in the retinas, as demonstrated by HE staining, PAS staining and ELISA kits, respectively. Immunofluorescence assay revealed that the protein expression of vascular endothelial growth factor (VEGF), VEGF receptor 2, hypoxia-inducible factor-1α(HIF-1α), and nuclear factor-κ B (NF-κB) p65 was upregulated in retinas compared with wild type ones, whereas berberine treatment could suppress their expression. Berberine prevent DR development through modulating the glucolipid metabolism and inhibiting the HIF-1α /VEGF/NF-κ B pathway, suggesting that berberine maybe a potential agent for the treatment of DR.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1691/ph.2021.01012 | DOI Listing |
Diabetes Obes Metab
September 2025
Department of Pharmacy, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Background: Diabetic retinopathy (DR) is a major complication of diabetes mellitus, characterised by retinal vasculopathy and oxidative stress. Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), has demonstrated cardiovascular benefits but has also been associated with mixed effects on DR progression. This study investigates the potential of semaglutide to attenuate DR progression by ameliorating retinal vasculopathy and oxidative stress in both in vivo and in vitro models.
View Article and Find Full Text PDFObjectives: To investigate whether quantitative retinal markers, derived from multimodal retinal imaging, are associated with increased risk of mortality among individuals with proliferative diabetic retinopathy (PDR), the most severe form of diabetic retinopathy.
Design: Longitudinal retrospective cohort analysis.
Setting: This study was nested within the AlzEye cohort, which links longitudinal multimodal retinal imaging data routinely collected from a large tertiary ophthalmic institution in London, UK, with nationally held hospital admissions data across England.
Exp Eye Res
September 2025
Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, 100 Haining Road, Hongkou District, Shanghai, 200080, China. Electronic address:
Purpose: A disintegrin-like and metalloprotease with thrombospondin type 1 motif 13 (ADAMTS13) has been found to increase and to be associated with diabetic retinopathy (DR). The study aimed to identify the role of ADAMTS13 in the pathogenesis of angiogenesis in DR.
Methods: ADAMTS13 expression was evaluated in human retinal microvascular endothelial cells (HRMVECs), vitreous sample from patients with proliferative DR and diabetic mice model using western blot, real time-quantitative PCR, immunofluorescence and ELISA.
Comput Methods Programs Biomed
September 2025
Key Laboratory of Social Computing and Cognitive Intelligence (Ministry of Education), Dalian University of Technology, Dalian, 116024, China; School of Computer Science and Technology, Dalian University of Technology, Dalian, 116024, China. Electronic address:
Background And Objective: Few-shot learning has emerged as a key technological solution to address challenges such as limited data and the difficulty of acquiring annotations in medical image classification. However, relying solely on a single image modality is insufficient to capture conceptual categories. Therefore, medical image classification requires a comprehensive approach to capture conceptual category information that aids in the interpretation of image content.
View Article and Find Full Text PDFInt J Surg
September 2025
Department of Ophthalmology, The First Affiliated Hospital of Dalian Medical University.
Diabetic retinopathy (DR) remains a leading cause of preventable blindness worldwide, with the affected population projected to reach 270 million by 2045. Our study analyzed 2 434 interventional trials registered between 2007 and 2024 in the Informa Pharma Intelligence database and found that anti-VEGF agents dominate the therapeutic landscape-bevacizumab represents 24.0 % of studies, ranibizumab 15.
View Article and Find Full Text PDF